Zevalin News and Research

RSS
Zevalin is a monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other types of B-cell tumors. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Ibritumomab binds to the protein called CD20, which is found on B cells. It is linked to the compound tiuxetan. This allows certain radioisotopes to be attached before it is given to a patient. It is a type of monoclonal antibody-chelator conjugate. Also called ibritumomab tiuxetan.
Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum signs definitive agreement to acquire Allos

Spectrum signs definitive agreement to acquire Allos

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum board authorizes $25 million stock repurchase program

Spectrum board authorizes $25 million stock repurchase program

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

Spectrum Pharmaceuticals enters agreement with Viropro to develop biosimilar rituximab

Spectrum Pharmaceuticals enters agreement with Viropro to develop biosimilar rituximab

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Target enrollment reached in belinostat Phase 2 study in Carcinoma of Unknown Primary

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting